As such, the treatment of MPN with IFN-α probably partially reinstates otherwise-defective tumor immune surveillance, as IFN-α can induce a complete hematological response and significantly reduce both the JAK2-mutated [100] and CALR-mutated allele burden [101,102]. The gene discussed is CALR; the disease is neoplasm.